- Home
- GMAB vs MRO Comparison
GMAB vs MRO Comparison
Compare GMAB & MRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- MRO
- Stock Information
- Founded
- GMAB 1999
- MRO 1887
- Country
- GMAB Denmark
- MRO United States
- Employees
- GMAB N/A
- MRO N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- MRO Oil & Gas Production
- Sector
- GMAB Health Care
- MRO Energy
- Exchange
- GMAB Nasdaq
- MRO Nasdaq
- Market Cap
- GMAB 15.0B
- MRO 16.0B
- IPO Year
- GMAB N/A
- MRO N/A
- Fundamental
- Price
- GMAB $20.65
- MRO $28.55
- Analyst Decision
- GMAB Buy
- MRO Buy
- Analyst Count
- GMAB 8
- MRO 17
- Target Price
- GMAB $43.00
- MRO $30.94
- AVG Volume (30 Days)
- GMAB 1.4M
- MRO 7.5M
- Earning Date
- GMAB 11-06-2024
- MRO 11-06-2024
- Dividend Yield
- GMAB N/A
- MRO 1.54%
- EPS Growth
- GMAB 14.35
- MRO N/A
- EPS
- GMAB 10.80
- MRO 2.32
- Revenue
- GMAB $2,967,926,227.00
- MRO $6,561,000,000.00
- Revenue This Year
- GMAB $30.31
- MRO $3.50
- Revenue Next Year
- GMAB $16.49
- MRO $0.39
- P/E Ratio
- GMAB $18.68
- MRO $12.31
- Revenue Growth
- GMAB 17.75
- MRO 1.66
- 52 Week Low
- GMAB $20.34
- MRO $21.81
- 52 Week High
- GMAB $32.88
- MRO $30.06
- Technical
- Relative Strength Index (RSI)
- GMAB 29.22
- MRO 56.13
- Support Level
- GMAB $20.34
- MRO $28.61
- Resistance Level
- GMAB $23.47
- MRO $29.13
- Average True Range (ATR)
- GMAB 0.46
- MRO 0.55
- MACD
- GMAB -0.12
- MRO 0.07
- Stochastic Oscillator
- GMAB 9.90
- MRO 57.51
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About MRO Marathon Oil Corporation
Marathon is an independent exploration and production company primarily focusing on unconventional resources in the United States. At the end of 2023, the company reported net proved reserves of 1.1 billion barrels of oil equivalent. Net production averaged 405 thousand barrels of oil equivalent per day in 2023 at a ratio of roughly 70% oil and NGLs and 30% natural gas.